AZV ČR to the development of the National Strategy for Clinical evaluation

On July 15, the Ministry of Health presented the first National Strategy for evaluation Clinical evaluation Medicinal Products in ČR (NS KHLP 2035) at a press conference. This is phase significant phase developing a modern, transparent, and competitive environment for conducting clinical evaluation the Czech Republic.

ČR Health Research Agency also played an active role in developing this strategy, particularly with regard to Specific Objective 1.3 – Support for non-commercial clinical evaluation, Specific Objective 3.2 – Raising awareness and enhancing the international appeal of the Czech Republic, and Specific Objective 4.2 – Creating a clear and functional entry point into the clinical evaluation system.

“Supporting non-commercial, academic clinical evaluation long evaluation one of our agency’s priorities. evaluation precisely these evaluation provide answers to a number of clinically significant questions and make it possible to test new diagnostic and therapeutic procedures in areas where such research is not sufficiently attractive to industry or commercial clinical research. The National Strategy provides an important framework for the further development of this area, and we are pleased that AZV ČR contribute to its development and will actively support the fulfillment of its objectives,” says Chair , Prof. Ondřej Slabý. 

Intensive international cooperation also helps to achieve the strategy’s objectives. Through the Ministry of Health andČR AZV ČR , the Czech Republic has been actively involved in the European health partnerships under the Horizon Europe programČR 2024. These partnerships contribute to improving the quality and accessibility of clinical evaluation strengthen the Czech Republic’s international standing in the field of clinical research.

The full press release from the Ministry of Health is available at this link.